• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vertex Pharmaceuticals (NQ:VRTX)

    547.92 +0.63 (+0.12%)
    Streaming Delayed Price Updated: 3:02 PM EDT, Aug 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Vertex Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Vertex to Participate in Upcoming September Investor Conferences
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex Reports Second Quarter 2026 Financial Results
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex to Acquire Crinetics Pharmaceuticals
    From Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex to Participate in Upcoming May Investor Conferences
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex Reports First Quarter 2026 Financial Results
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex to Announce First Quarter 2026 Financial Results on May 4th
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
    Via ACCESS Newswire
    News headline image
    Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex to Participate in Upcoming March Investor Conferences
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
    Issued on behalf of Avant Technologies Inc. 
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
    Issued on behalf of Avant Technologies Inc. 
    From USA News Group
    Via GlobeNewswire
    News headline image
    Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.